MYC is now known to be a potent oncogene and dysregulation of MYC, as a result of gene rearrangement or other mechanism, has been shown to be associated with extremely aggressive clinical behavior in lymphoma patients [1, 2]. This evidence concerns the gene MYC and lymphoma.